{
    "clinical_study": {
        "@rank": "41826", 
        "arm_group": [
            {
                "arm_group_label": "JNJ-38518168", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo / JNJ-38518168", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the impact of JNJ-38518168 on rheumatoid arthritis\n      (RA) disease-related biomarkers in synovial biopsy tissue and blood in participants with\n      active RA despite methotrexate (MTX) therapy and to assess the safety and tolerability of\n      JNJ-38518168 over one year."
        }, 
        "brief_title": "A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized (participants assigned to treatment by chance), double-blind\n      (participants and study personnel will not know what treatment is being given),\n      placebo-controlled (a placebo appears identical to a study drug, but contains no active\n      ingredients), parallel-group (treatments will be given to groups of participants at the same\n      time) study. Participants will be randomly assigned in a 3:1 ratio to receive either\n      JNJ-38518168 for 52 weeks or receive matching placebo for 12 weeks, followed by JNJ-38518168\n      for 40 weeks. The total duration of participation will be approximately 60 weeks for all\n      participants, including a screening visit and follow-up visits. Safety and tolerability of\n      JNJ-38518168 will be evaluated by monitoring adverse events reported by participants\n      throughout the study . In addition, results from clinical laboratory tests,\n      electrocardiograms, vital signs measurements, and physical examinations performed during the\n      study will be monitored."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have had rheumatoid arthritis (RA) for at least 6 months prior to the date of signing\n             the informed consent at screening\n\n          -  Be positive for either anti-cyclic citrullinated peptide (anti-CCP) antibody or\n             rheumatoid factor (RF) in serum at screening\n\n          -  Have active RA defined for the purpose of this study as persistent disease activity\n             with both of the following criteria: At least 4 swollen and 4 tender joints using a\n             66/68 joint count. At the time of screening, one of the tender or swollen joints or\n             both must include the non-prosthetic knee to be biopsied; and serum C-reactive\n             protein (CRP_ \u2265 0.60 mg/dL at screening\n\n          -  Have been treated with and tolerated oral methotrexate (MTX) treatment at doses from\n             10 mg/week to 25 mg/week inclusive, for a minimum of 3 months prior to the date of\n             signing the informed consent at screening and must have a stable MTX dose for a\n             minimum of 8 weeks prior to the date of signing the informed consent at screening and\n             continue to receive the same MTX dose at Week 0\n\n          -  If using nonsteroidal anti-inflammatory drugs (NSAIDs) or other analgesics (pain\n             relievers) regularly for RA, the participant must have been on a stable dose for at\n             least 2 weeks prior to the first administration of study agent. If not using NSAIDs\n             or other analgesics for RA at Week 0, the participant must have not received NSAIDs\n             or other analgesics for RA for at least 2 weeks prior to the first administration of\n             study agent\n\n        Exclusion Criteria:\n\n          -  Has inflammatory diseases other than RA\n\n          -  Has a history of juvenile idiopathic arthritis (JIA)\n\n          -  Has current signs or symptoms of liver or renal insufficiency or cardiac, vascular,\n             pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or\n             metabolic disturbances that are severe, progressive, or uncontrolled"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862224", 
            "org_study_id": "CR100963", 
            "secondary_id": [
                "38518168ARA2003", 
                "2011-006325-18"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "JNJ-38518168", 
                "description": "JNJ-38518168 30 mg once daily, Week 0 to Week 52.", 
                "intervention_name": "JNJ-38518168", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo / JNJ-38518168", 
                "description": "Matching placebo once daily (Week 0 to Week 12).", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo / JNJ-38518168", 
                "description": "JNJ-38518168 30 mg once daily, Week 12 to Week 52.", 
                "intervention_name": "Placebo / JNJ-38518168", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Active rheumatoid arthritis despite methotrexate therapy", 
            "JNJ-38518168", 
            "Synovial"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "link": {
            "description": "To learn how to participate in this trial please click here.", 
            "url": "http://pam.sylogent.com/cr/CR100963"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frederick", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mesquite", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chisinau", 
                        "country": "Moldova, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Moldova, Republic of"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Biomarkers may include, but are not limited to, inflammatory markers and cytokines; synovium/cartilage/bone markers; and gene expression profiles.", 
            "measure": "Assessment of rheumatoid arthritis (RA) biomarkers", 
            "safety_issue": "No", 
            "time_frame": "Up to Week 52"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862224"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants reporting adverse events as a measure of safety and tolerability", 
            "safety_issue": "No", 
            "time_frame": "Up to Week 56"
        }, 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}